Tuberculosis Drugs Market
- 2026 年市場規模
- USD 2.51 Bn
- 2033 年預估規模
- USD 3.49 Bn
- 年複合成長率 CAGR
- 4.77%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Tuberculosis Drugs Market, By Therapy Type (First Line Therapy, and Second Line Therapy), By Disease type (Active TB, and Latent TB), By End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) , By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.
The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.
Market Dynamics
Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.
Key features of the study:
• This report provides in-depth analysis of the market, tuberculosis drugs market size (USD Bn), and compound annual growth rate (CAGR%) for the forecast period (2026 – 2033), considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tuberculosis drugs market based on the following parameters such as company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
• Key players covered as a part of this study include, include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to product launches, governmental initiatives, market expansion, and marketing tactics
• The global tuberculosis drugs market report caters to various stakeholders in this industry such as investors, product manufacturers, distributors, and suppliers of TB drugs, research and consulting firms, new entrants, and financial analysts
Market Segmentation
• By Therapy Type,
o First Line Therapy
Isoniazid (INH)
rifampicin (RIF)
Ethambutol (EMB)
Pyrazinamide (PZA)
Streptomycin (SM).
o Second Line Therapy
o Fluoroquinolones
o Injectable antituberculosis drugs
• By Disease Type,
o Active TB
o Latent TB
• By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• By Region
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Tuberculosis Drugs Market - Competitive Landscape
o Johnson & Johnson Services, LLC
o Lupin Ltd
o Novartis AG
o Macleods Pharmaceuticals Ltd.
o Otsuka Pharmaceutical Co., Ltd
o Pfizer Inc.
目錄 Table of Contents
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Therapy Type
Market Snippet, By Disease Type
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Regulatory Landscape
o Drug Recall
o Porter’s Five Forces Model
4. Global Tuberculosis Drugs Market, By Therapy Type, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2017 – 2033
Segment Trends
o First Line Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
o Isoniazid (INH)
o rifampicin (RIF)
o Ethambutol (EMB)
o Pyrazinamide (PZA)
o Streptomycin (SM).
o Second Line Therapy
Fluoroquinolones
Injectable antituberculosis drugs
5. Global Tuberculosis Drugs Market, By Disease Type, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2017 – 2033
Segment Trends
o Active TB
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
o Latent TB
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
6. Global Tuberculosis Drugs Market, By Distribution Channel, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2017 – 2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026 – 2033, (USD Bn)
7. Global Tuberculosis Drugs Market, By Region, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, By Region, 2018– 2033
Regional Trends
o North America
Market Size and Forecast, By Therapy Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Bn)
o U.S.
o Canada
o Europe
Market Size and Forecast, By Therapy Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Size and Forecast, By Therapy Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Bn)
o China
o Japan
o India
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
Market Size and Forecast, By Therapy Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
Market Size and Forecast, By Therapy Type 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country/Region, 2026 – 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
o Middle East
Market Size and Forecast, By Therapy Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Disease Type, 2026 – 2033, (USD Bn)
Market Size and Forecast, By Country, 2026 – 2033, (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
8. Competitive Landscape
o Company Profiles
Lupin ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
Johnson & Johnson Services, LLC
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
Novartis AG
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
Macleods Pharmaceuticals Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
Otsuka Pharmaceutical Co., Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們